What is Flow Neuroscience?
Based in Malmoe, Sweden, Flow Neuroscience operates at the intersection of medical technology and digital health. The company specializes in transcranial direct current stimulation (tDCS) technology, providing a non-invasive treatment option for depression. By integrating this hardware with a proprietary behavioral therapy application, Flow Neuroscience offers a holistic, patient-centric solution that addresses the growing global demand for accessible mental health interventions. The company's market position is defined by its commitment to clinical rigor and its ability to bridge the gap between traditional psychiatric care and modern, app-based digital health platforms.
How much funding has Flow Neuroscience raised?
Flow Neuroscience has raised a total of $11.9M across 3 funding rounds:
Angel/Seed
$1.1M
Other Financing Round
$1.5M
Series A
$9.3M
Angel/Seed (2018): $1.1M with participation from SOSV and Khosla Ventures
Other Financing Round (2019): $1.5M led by Khosla Ventures
Series A (2021): $9.3M supported by Zühlke Ventures, Khosla Ventures, and Swiss Health Ventures
Key Investors in Flow Neuroscience
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, with a strong focus on health, AI, and consumer sectors.
SOSV
SOSV is a multi-stage venture capital investor that provides intellectual and financial capital to accelerate founders big ideas, particularly in deep tech and health innovation.
Zühlke Ventures
Zühlke Ventures is a specialized investment firm that focuses on high-tech startups, providing both capital and engineering expertise to drive medical and industrial innovation.
What's next for Flow Neuroscience?
With the infusion of capital from its latest funding round, Flow Neuroscience is well-positioned to accelerate its clinical development and expand its commercial footprint. The company is expected to focus on scaling its operations, enhancing its digital therapy platform, and potentially pursuing regulatory milestones in new international markets. As the digital therapeutics sector continues to mature, Flow Neuroscience's ability to demonstrate long-term efficacy and user engagement will be critical for its next phase of growth. Investors are likely looking for the company to solidify its competitive advantage through continued innovation in neurostimulation and data-driven patient outcomes.
See full Flow Neuroscience company page
